The antimicrobial peptide pardaxin exerts potent anti-tumor activity against canine perianal gland adenoma
Metrics: PDF 1629 views | HTML 2342 views | ?
Chieh-Yu Pan1, Chao-Nan Lin2, Ming-Tang Chiou2, Chao Yuan Yu3, Jyh-Yih Chen4 and Chi-Hsien Chien2
1 Department and Graduate Institute of Aquaculture, National Kaohsiung Marine University, Nanzih Dist., Kaohsiung, Taiwan
2 Graduate Institute and Department of Veterinary Medicine, College of Veterinary Medicine, National Pingtung University of Science and Technology, Neipu, Pingtung, Taiwan
3 Genomics BioSci & Tech Co., Ltd., Xizhi Dist., New Taipei, Taiwan
4 Marine Research Station, Institute of Cellular and Organismic Biology, Academia Sinica, Jiaushi, Ilan, Taiwan
Chi-Hsien Chien, email:
Jyh-Yih Chen, email:
Keywords: antimicrobial peptide, pardaxin, cancer treatment, perianal gland adenoma, canine, intratumoral treatment
Received: October 25, 2014 Accepted: December 09, 2014 Published: December 10, 2014
Pardaxin is an antimicrobial peptide of 33 amino acids, originally isolated from marine fish. We previously demonstrated that pardaxin has anti-tumor activity against murine fibrosarcoma, both in vitro and in vivo. In this study, we examined the anti-tumor activity, toxicity profile, and maximally-tolerated dose of pardaxin treatment in dogs with different types of refractory tumor. Local injection of pardaxin resulted in a significant reduction of perianal gland adenoma growth between 28 and 38 days post-treatment. Surgical resection of canine histiocytomas revealed large areas of ulceration, suggesting that pardaxin acts like a lytic peptide. Pardaxin treatment was not associated with significant variations in blood biochemical parameters or secretion of immune-related proteins. Our findings indicate that pardaxin has strong therapeutic potential for treating perianal gland adenomas in dogs. These data justify the veterinary application of pardaxin, and also provide invaluable information for veterinary medicine and future human clinical trials.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.